This study aims to investigate the Turkish validity and reliability of the International Fitness Scale (IFIS) and the Self-Perceived Health-Related Physical Fitness Questionnaire for Children (SPHQ-C) aged 10-17. The measurement tools were translated into Turkish by two independent researchers and back-translated. Then, the content validity was established with a group of 13 individuals (Sample 1) who presented to the sports medicine clinic. The pilot application phase was initiated. A sample of 372 individuals (Sample 2) studying in the provincial center was selected for piloting the measurement tools with the ALPHA-FIT Test Battery. The test-retest application of the measurement tools with a 15-day interval was carried out with 207 individuals (Sample 3) not included in Sample 2. The authors calculated that the content validity ratio values for the items in the IFIS ranged from 0.85 to 1.00, with a content validity index of 0.94 for the scale. In the SPHQ-C, these values were found to be between 0.92 and 1.00, with a content validity index of 0.99. According to the Z-score difference analysis for both measurement tools, the construct validity of all items was achieved ( < 0.05). In the Bland-Altman plot test conducted for the IFIS-TR, the mean difference was calculated as 0.11, the standard deviation of the differences was 1.57, and the -value was determined as 0.31. For the SPHQ-C-TR, the mean difference was -0.15, the standard deviation of the differences was 1.95, and the -value was determined as 0.26. The Kappa coefficients for the items of the IFIS-TR ranged from 0.45 to 0.52, while for the SPHQ-C-TR, the Kappa coefficients ranged from 0.47 to 0.75. Confirmatory factor analysis conducted on Sample 2 confirmed model fit indices with covariance among some items of the measurement tools (IFIS-TR: e1-e3; SPHQ-C-TR: e1-e2, e1-e3, e2-e3, e3-e4, e6-e7, e8-e9). The IFIS and SPHQ-C measurement tools have been adapted into Turkish, and their validity and reliability have been established.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528336 | PMC |
| http://dx.doi.org/10.3390/children10091546 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Immunotherapy of Alzheimer's disease (AD) is a promising approach to reducing the accumulation of beta-amyloid, a critical event in the onset of the disease. Targeting the group II metabotropic glutamate receptors, mGluR2 and mGluR3, could be important in controlling Aβ production, although their respective contribution remains unclear due to the lack of selective tools.
Method: 5xFAD mice were chronically treated by a brain penetrant camelid single domain antibody (VHH or nanobody) that is an activator of mGluR2.
Drug Development.
Alzheimers Dement
December 2024
Center for Health + Technology, University of Rochester Medical Center, Rochester, NY, USA.
Background: In preparation for therapeutic trails involving patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI), there is a need for valid, disease-specific caregiver-reported outcome (CRO) measures capable of tracking symptomatic burden in response to therapy over time. CROs are useful tools in clinical trials for individuals with AD, MCI, and dementia who are unable to self-report. In addition, CROs are accepted by the United States Food and Drug Administration to support regulatory claims.
View Article and Find Full Text PDFBackground: Clinical outcome assessments (COAs) that measure functional capacities are key tools to evaluate efficacy in Alzheimer's disease (AD) clinical trials. The Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale is frequently used to assess changes in both basic and instrumental activities of daily living, but there is no clear consensus on what magnitude of change on this scale may be considered clinically meaningful. To address this question, we conducted anchor-based analyses (as recommended by the FDA) to explore meaningful within-patient/participant change thresholds on the ADCS-ADL.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path institute, Tucson, AZ, USA.
Background: To help improve the Alzheimer's disease (AD) therapeutics research and development process, the Critical Path for Alzheimer's Disease (CPAD) Consortium at the Critical Path Institute (C-Path) provides a neutral framework for the drug development industry, regulatory agencies, academia, and patient advocacy organizations to collaborate. CPAD's extensive track record of developing regulatory-grade quantitative drug development tools motivates sponsors to share patient-level data and neuroimages from clinical trials. CPAD leverages these data and uses C-Path's core competencies in data management and standardization, quantitative modeling, and regulatory science to develop tools that help de-risk decision making in AD drug development.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
The Chinese University of Hong Kong, Hong Kong, China.
Background: Cognitive training and exercise intervention are suggested for enhancing cognitive functions in people with mild cognitive impairment (MCI). The use of virtual reality (VR) has been applied in cognitive training and exercise intervention in recent decades. However, it is still unclear whether VR-based intervention is a useful means to enhance cognitive functions in people with MCI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!